Aphexda
(Motixafortide)ApprovedPeptide
Jazz PharmaceuticalsMotixafortide is used alongside filgrastim to prepare cells for stem cell transplantation in multiple myeloma patients. It works by mobilizing stem cells into the bloodstream so they can be collected for transplant purposes.[2] Aphexda is currently approved and in use across 4 indications[4].[1]
Aphexda is one of 176 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Approved.
4
Indications
7
Total Trials
5
Active Trials
175
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Belamaf
GSKPhase 3
TALVEY
Johnson & JohnsonPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Vepesid
AAvyxa
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
Aphexda
Jazz PharmaceuticalsApproved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Mezigdomide
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease3 trials
Pancreatic Adenocarcinoma1 trial
Regulatory
FDA Approval Timeline[5]
Sep 8, 2023
APHEXDA
NDA NDA217159
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aphexda drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Motixafortide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]